Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nipocalimab versus intravenous immunoglobulin in pregnancies at risk of fetal and neonatal alloimmune thrombocytopenia
ISRCTN17841362Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of nipocalimab and immune globulin in fetomaternal alloimmune thrombocytopenia (FMAIT), sponsored by Janssen Pharmaceutical. Primary endpoint: Primary composite neonatal/fetal outcome. Started Oct 2024; status: recruiting.
02
Drugs
nipocalimabimmune globulin
03
Conditions
fetomaternal alloimmune thrombocytopenia (FMAIT)
Beyond the preview
Go deeper on ISRCTN17841362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17841362.